

## Recording of Diabetes on Death Certificates of Decedents With Type 1 Diabetes in DCCT/EDIC

Diabetes Care 2018;41:e158-e160 | https://doi.org/10.2337/dc18-1704

Laura N. McEwen,<sup>1</sup> Pearl G. Lee,<sup>1,2</sup> Jye-Yu C. Backlund,<sup>3</sup> Catherine L. Martin,<sup>1</sup> and William H. Herman<sup>1,4</sup>

Diabetes is frequently not recorded on the death certificates of decedents with type 2 diabetes (1). Less is known about the recording of diabetes for decedents with type 1 diabetes (2–4). We describe the recording of diabetes on death certificates for decedents with type 1 diabetes who participated in the Diabetes Control and Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions and Complications (EDIC) (ClinicalTrials.gov reg. nos. NCT00360815 and NCT00360893, respectively).

We investigated whether the word(s) "diabetes," "diabetes mellitus," "type 1 diabetes," "type 2 diabetes," or their abbreviations appeared as the underlying cause of death (last listed cause of death in part I of the death certificate) or anywhere on the death certificate. We defined end-stage renal disease, chronic renal failure, and diabetic ketoacidosis as diabetes-related underlying causes of death. Covariates included age and duration of diabetes at death, sex, race/ethnicity, education, last recorded treatment group, BMI, and smoking status at baseline. Study coordinators at each DCCT/EDIC site determined whether the person who signed the death certificate was the decedent's primary care physician (PCP). The t test and  $\chi^2$  test were used to identify variables associated with recording diabetes. By April 2016, 134 DCCT/EDIC participants had died. Death certificates were available for 95 (71%), and 91 recorded a cause of death. The characteristics of the 43 decedents without death certificates did not differ from the 91 with death certificates that recorded a cause of death. The characteristics of decedents are shown in Table 1.

Forty-four percent of decedents had diabetes recorded anywhere on the death certificate, and 16% had diabetes recorded as the underlying cause of death. Underlying causes of death are shown in Table 1. Diabetes was recorded anywhere on the death certificates for 57% of decedents who died of cardiovascular disease. When the underlying cause of death was cancer, none of the death certificates recorded diabetes. When suicide/accident/injury and "other" were the underlying causes of death, 18% and 17% of death certificates, respectively, recorded diabetes.

Older decedents were less likely to have diabetes recorded anywhere on the death certificate (Table 1). Seventy-five percent of decedents <40 years of age, 41% of those 40–49, 48% of those 50–59, and 13% of decedents  $\geq$ 60 had diabetes recorded anywhere (P = 0.0137), and 50% of decedents <40 years of age, 13% of those 40–49, 15% of those 50–59, and none who were  $\geq$  60 had diabetes recorded as the underlying cause (P = 0.0044).

If the PCP was the certifying physician, diabetes was more likely to be recorded on the death certificate (Table 1). The credentials of the certifier, place and time of death, and performance of an autopsy were not associated with recording of diabetes (Table 1).

Of decedents with diabetes recorded anywhere, 64% did not specify diabetes type, 33% had type 1 diabetes specified, and 3% had type 2 diabetes incorrectly specified. Only 27% of decedents with diabetes recorded as the underlying cause of death had type 1 diabetes specified.

In summary, diabetes was recorded anywhere on the death certificate for 44% of decedents with long-standing type 1 diabetes and as the underlying cause of death for 16% of decedents. These results are similar to those from a meta-analysis that assessed decedents with type 1 and type 2 diabetes (1) but lower than those from previous studies that focused on decedents with insulintreated diabetes (58% of such decedents in the U.K. had diabetes recorded anvwhere and 15% had diabetes recorded as the underlying cause of death) (2) and type 1 diabetes (84% of such decedents in Tazmania had diabetes recorded anywhere and 47% had diabetes recorded

<sup>&</sup>lt;sup>1</sup>Department of Internal Medicine, University of Michigan, Ann Arbor, MI

<sup>&</sup>lt;sup>2</sup>Geriatric Research Education and Clinical Centers (GRECC), Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI <sup>3</sup>The George Washington University, Rockville, MD

<sup>&</sup>lt;sup>4</sup>Department of Epidemiology, University of Michigan, Ann Arbor, MI

Corresponding author: Laura N. McEwen, Imattei@med.umich.edu.

Received 9 August 2018 and accepted 10 September 2018.

<sup>© 2018</sup> by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

## Table 1—Characteristics of DCCT/EDIC decedents with type 1 diabetes according to whether or not diabetes was recorded anywhere on the death certificate

	All decedents	Decedents with diabetes recorded	Decedents with diabetes not recorded	P value
Number (%)	91 (100)	40 (44)	51 (56)	1 Value
Underlying cause of death <sup>†</sup> Cardiovascular Cancer Diabetes-related Suicide/accident/injury Respiratory/infection/sepsis Other	28 (31) 21 (23) 18 (20) 11 (12) 7 (8) 6 (7)	16 (57) 0 (0) 18 (100) 2 (18) 3 (43) 1 (17)	12 (43) 21 (100) 0 (0) 9 (82) 4 (57) 5 (83)	<0.0001
Age at death (years)	$51\pm9$	$48 \pm 8$	$54 \pm 9$	0.0032*
Duration of diabetes at death (years)	$28 \pm 8$	26 ± 7	29 ± 8	0.1711
Sex Female Male	34 (37) 57 (63)	14 (35) 26 (65)	20 (39) 31 (61)	0.6799
Race/ethnicity White Nonwhite	87 (96) 4 (4)	37 (93) 3 (8)	50 (98) 1 (2)	0.2008
Education < College ≥ College	54 (59) 37 (41)	26 (65) 14 (35)	28 (55) 23 (45)	0.3304
Cigarette smoker	26 (29)	14 (35)	26 (65)	0.2293
BMI at baseline (kg/m <sup>2</sup> )	24 ± 3	23 ± 3	24 ± 3	0.1030
Last recorded treatment method Pump Injections	12 (13) 79 (86)	4 (10) 36 (90)	8 (16) 43 (84)	0.4262
PCP as certifier No Yes	67 (89) 8 (11)	24 (80) 6 (20)	43 (96) 2 (4)	0.0325*
Certifier type Physician Medical examiner Coroner	42 (56) 25 (33) 8 (11)	18 (55) 13 (39) 2 (6)	24 (57) 12 (29) 6 (14)	0.3978
Medical examiner contacted No Yes	28 (44) 36 (56)	12 (43) 16 (57)	16 (44) 20 (56)	0.8990
Place of death Residence Hospital Other	28 (38) 30 (41) 15 (21)	13 (37) 17 (49) 5 (14)	15 (39) 13 (34) 10 (26)	0.3290
Time of death 8 A.M.–5 P.M. 5 P.M.–8 A.M.	29 (48) 31 (52)	13 (50) 13 (50)	16 (47) 18 (53)	0.8213
Autopsy performed No Yes	51 (74) 18 (26)	24 (75) 8 (25)	27 (73) 10 (27)	0.8484

Data are frequency (percent) or mean  $\pm$  SD, unless otherwise indicated. T1D, type 1 diabetes. \*P < 0.05. †When stratified by recording of diabetes anywhere, row percents are shown.

as the underlying cause of death) (3). A German study reported that 71% of decedents with physician-diagnosed type 1 diabetes had diabetes recorded anywhere (4).

As in our study, prior studies have found that diabetes is recorded more frequently when cardiovascular disease is the underlying cause of death and less frequently when the underlying cause of death is cancer (2,4). None of the previous studies examined whether type 1 diabetes was correctly specified. We found that when diabetes is recorded, type 1 diabetes is correctly specified only 33% of the time. Consistent with our previous study of decedents with type 2 diabetes (5), we found that PCP certifiers are more likely to record diabetes, suggesting that they are more familiar with the decedents' medical histories.

While diabetes is known to be underreported on death certificates, we did not find that diabetes was more likely to be recorded for decedents with type 1 diabetes. Because of this substantial underreporting, analyses of death certificates alone will underestimate mortality among people with type 1 diabetes. Cohort studies are most appropriate to describe mortality in people with type 1 diabetes.

Acknowledgments. The authors thank the DCCT/EDIC Research Group for permission to use the data. A complete list of participants in the DCCT/EDIC Research Group is presented in the online Supplementary Appendix of the article published in N Engl J Med 2017;376:1507-1588. Funding. The project was supported in part by the National Institute of Diabetes and Digestive and Kidney Diseases grant number P30DK020572 (Michigan Diabetes Research Center). The DCCT/ EDIC has been supported by cooperative agreement grants (1982-1993, 2012-2017, 2017-2022) and contracts (1982-2012) with the Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases (current grant numbers U01 DK094176 and U01 DK094157) and through support from the National Eye Institute, the National Institute of Neurological Disorders and Stroke, the General Clinical Research Centers Program (1993-2007), and the Clinical Translational Science Center Program (2006-present), Bethesda, MD.

The following companies have provided free or discounted supplies or equipment to support participants' adherence to the study: Abbott Diabetes Care (Alameda, CA), Animas (Westchester, PA), Bayer Diabetes Care (North America Headquarters, Tarrytown, NY), Becton Dickinson (Franklin Lakes, NJ), Eli Lilly (Indianapolis, IN), Extend Nutrition (St. Louis, MO), Insulet Corporation (Bedford, MA), LifeScan (Milpitas, CA), Medtronic Diabetes (Minneapolis, MN), Nipro Home Diagnostics (Fort Lauderdale, FL), Nova Diabetes Care (Billerica, MA), Omron (Shelton, CT), Perrigo Diabetes Care (Allegan, MI), Roche Diabetes Care (Indianapolis, IN), and Sanofi (Bridgewater, NJ).

Industry contributors had no role in the DCCT/ EDIC study.

Duality of Interest. No potential conflicts of interest relevant to this article were reported. Author Contributions. L.N.M. researched the data, performed statistical analyses, wrote the manuscript, and reviewed and edited the manuscript. P.G.L. and C.L.M. contributed to the discussion and reviewed and edited the manuscript. J.-Y.C.B. researched the data and performed statistical analyses. W.H.H. designed the study, contributed to the discussion, and reviewed and editeusion, and reviewed and editeusion, and reviewed and edited the manuscript. L.N.M. and W.H.H. are the guarantors of this work and, as

such, had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

## References

1. Saydah SH, Geiss LS, Tierney E, Benjamin SM, Engelgau M, Brancati F. Review of the performance of methods to identify diabetes cases among vital statistics, administrative, and survey data. Ann Epidemiol 2004;14:507–516 2. Raymond NT, Langley JD, Goyder E, Botha JL, Burden AC, Hearnshaw JR. Insulin treated diabetes mellitus: causes of death determined from record linkage of population based registers in Leicestershire, UK. J Epidemiol Community Health 1995;49:570–574

3. Riley MD, McCarty DJ, Couper DJ, Humphrey ARG, Dwyer T, Zimmet PZ. The 1984 Tasmanian insulin treated diabetes mellitus prevalence cohort: an eight and a half year mortality follow-up

investigation. Diabetes Res Clin Pract 1995;29: 27-35

4. Mühlhauser I, Sawicki PT, Blank M, Overmann H, Richter B, Berger M. Reliability of causes of death in persons with type I diabetes. Diabetologia 2002;45:1490–1497

5. McEwen LN, Pomeroy NE, Onyemere K, Herman WH. Are primary care physicians more likely to record diabetes on death certificates? Diabetes Care 2008;31:508–510